BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
This small early phase trial is concerned with an important issue, DUs in SSc. Based on preliminary evidence it is reasonable to conduct a trial of MSCs for this complication. I am strongly in favor of a trial such as this but the bottom line is that I think much more information, especially regarding measurement issues, could be achieved in this early phase study. And this group is capable of doing that so I hope that they will incorporate some of the suggestions below.
The value of an early trial depends on exactly what they will look for and how it will inform a larger trial. They mention objectives as being feasibility, side effects and potential benefit
In terms of feasibility, what are the possible issues they foresee, such as recruitment rate, getting the cells to the patient on time, etc etc..? What type of results would they use to conclude the larger trial will be feasible? I think they have dealt well with side effects.
I have addressed issue of potential benefit below. Key issues are the methods of assessing efficacy, the need for placebo and the effects of having 3 different patterns of injections. These need to be explored better.
"Based on the available data, and given that it is unknown which injections are most effective (at a distance versus local), we designed an injection protocol that combines two distant IM injection sites with six IM injection sites closer to the fingers: 2x forearm, 4x mm. interossei, thenar and hypothenar musculature".
I do not feel convinced by the data that distant IM injection makes a lot of sense. Much of the IM injections were actually given around the ulcers. Even if such injection have pro-angiogenic properties it is hard to understand how injection in muscle distant from the sites would have benefit. Are there any studies showing how pathophysiologically this may happen? The statement that IM injection may allow bypassing IV issues does not make a priori sense in terms of efficacy even if it does in terms of vascular side effects.
So before proceeding I would like to see much better evidence that injection far from the ulcer site has the potential to be beneficial.
The there is the issue of several different injection sites. Although power may not be an issue in an early phase study, one of their goals is to assess potential efficacy of IM administration of MSCs. The 3 different patterns of injection sites leaves them with only 3 participants in each group. I do not see how any potential efficacy could be assessed.
So we have to better understand the ultimate goal. Is the ultimate study gong to somehow compare these 3 methods, thus requiring a huge number of participants? Or do they expect to be able to choose one of these methods form this small trial, in which case that is unlikely because of the small size.
Although they are correct that in a large study there will be a need for a placebo arm, that is not necessarily true for this size study. How exactly will the placebo arm help them? I suppose one possibility would be to see if observers can remain blinded to the type of injection, perhaps biased by local side effects. But they have to show us the relevance of the placebo group based on their ultimate goals and data analyses rather than referring to statement about the need for placebo in large phase 3 trials.
Will they quantitate capillaroscopy? What changes do they expect? Increase number of vessels? Good chance to assess feasibility of that quantitation.
It seems that they intend to use the area of the ulcers as a primary outcome for efficacy. This trial would be an excellent opportunity to show that in SSc that may be a feasible, reliable and valid method. Therefore these endpoints should be used in this trial. That requires much more detailed data on exactly how the photographs are performed. How reliable are the photos themselves day to day in terms of reproducibility.? The same applies to calculating areas from the photos. Which ulcers exactly will be included? All present ulcers? Only certain of the present ulcers? What if new ulcers appear but old ones resolve or improve? How will that be scored?
GENERAL COMMENTS
This is an important clinical trial to solve the effect of MSC injection on DUs in SSc patients. There is increasing evidences that MSC enhance angiogenesis, suppress inflammation in vitro and in vivo. In addition, to examine the safety of the injection of MSC is important. Several study using MSC injection already reported that allogeneic MSC injection did not have serious adverse events. This study also examine about this in SSc patients. DU activity in SSc patients is depend on the temperature. DU in SSc patients usually deteriorates in the winter, and improves in the summer. When will you start this clinical trial? It is necessary to define the starting time in this trial. If placebo control injection is initiated in the summer, DU may be improved by the increasing temperature, even if the placebo is injected. The primary objective of this trial is to assess the safety of the treatment. The safety outcomes can also inform the feasibility of a larger trial by providing more insight into adverse event rate. A larger trial will be deemed feasible if we can recruit the required N within a reasonable timeframe and if the treatment is safe (no SAEs that can be attributed to the treatment). We have added a description of feasibility aspects that will be assessed (line 336-337 in the marked version, line 299-300 in the clean version).
REVIEWER
2) I do not feel convinced by the data that distant IM injection makes a lot of sense. Much of the IM injections were actually given around the ulcers. Even if such injection have pro-angiogenic properties it is hard to understand how injection in muscle distant from the sites would have benefit. Are there any studies showing how pathophysiologically this may happen? The statement that IM injection may allow bypassing IV issues does not make a priori sense in terms of efficacy even if it does in terms of vascular side effects. So before proceeding I would like to see much better evidence that injection far from the ulcer site has the potential to be beneficial.
The study protocol is based on preclinical and clinical studies in critical ischemia of the lower extremity, in which cells were injected in the upper leg and/or the calf muscles. In some studies this was combined with injections in/around the ulcers. As of now, it is not clear which injections (close to the ulcer or at a distance) are responsible for the treatment effect. Pathophysiological mechanisms by which distant injections might have benefit are 1) polarization of resident tissue immune cells towards more regenerative phenotypes, which then may migrate towards the wound site 2) secretion of paracrine factors that enhance local tissue repair responses. We have revised the introduction to better reflect the mechanism of action of the treatment. Additionally, this study is focused on establishing the safety of the protocol and the administration route. Even though it is not known which injection site is most effective, we will have gathered data on the safety of all injection sites. Future studies can then focus on comparing different protocols. There are also solid reasons against both intravascular injection and injections at the ulcer site. Intravenous injection has been shown to lead to trapping of MSCs in the lung. Injections at the ulcer site could possibly exacerbate existing infections by inoculation of tissues through the needle tracts.
3) The there is the issue of several different injection sites. Although power may not be an issue in an early phase study, one of their goals is to assess potential efficacy of IM administration of MSCs. The 3 different patterns of injection sites leaves them with only 3 participants in each group. I do not see how any potential efficacy could be assessed. So we have to better understand the ultimate goal. Is the ultimate study gong to somehow compare these 3 methods, thus requiring a huge number of participants? Or do they expect to be able to choose one of these methods form this small trial, in which case that is unlikely because of the small size.
As depicted in figure 1 , the trial will contain only 2 arms: one placebo arm and one verum arm. All participants will receive 8 injections. We have amended the text to better reflect this. (line 285 in the marked version, line 250 in the clean version) 4) Although they are correct that in a large study there will be a need for a placebo arm, that is not necessarily true for this size study. How exactly will the placebo arm help them? I suppose one possibility would be to see if observers can remain blinded to the type of injection, perhaps biased by local side effects. But they have to show us the relevance of the placebo group based on their ultimate goals and data analyses rather than referring to statement about the need for placebo in large phase 3 trials.
The rationale for using a placebo in this study is twofold, as we address in the design paragraph: -In studies assessing 'stem cell based' treatments a significant placebo effect can be seen. This was seen in our own JUVENTAS trial, but also in a meta-analysis that showed a significant trial effect in early, uncontrolled trials in stem cell therapy for cardiac disease [1] . Regarding the references we cited; Chung et al, specifically pose that controlled trials are strongly advised to evaluate new therapies for DUs in SSc, including in phase II of drug development. This is reiterated in Khanna et al who state that all trials should be well controlled, particularly phase 2-3 trials; randomization is considered the most appropriate approach even in very early trials, and blinding is also considered most appropriate; their recommendations explicitly do not only cover large phase 3 trials. We have amended the text to better reflect this rationale. (line 208-224) 5) Will they quantitate capillaroscopy? What changes do they expect? Increase number of vessels? Good chance to assess feasibility of that quantitation.
Capillaroscopic images will be scored both qualitatively and semi-quantitatively, using standardized and validated methods. We have added a brief description to the outcomes and follow-up section (line 352-353 in the marked version, line 315-316 in the clean version). Indeed, an increase in the number of vessels and/or neoangiogenesis has been reported after cell based treatment.
6) It seems that they intend to use the area of the ulcers as a primary outcome for efficacy. This trial would be an excellent opportunity to show that in SSc that may be a feasible, reliable and valid method. Therefore these endpoints should be used in this trial. That requires much more detailed data on exactly how the photographs are performed. How reliable are the photos themselves day to day in terms of reproducibility.? The same applies to calculating areas from the photos. Which ulcers exactly will be included? All present ulcers? Only certain of the present ulcers? What if new ulcers appear but old ones resolve or improve? How will that be scored?
We thank the reviewer for their helpful suggestions for establishing ulcer area as an endpoint in clinical trials assessing therapies for digital ulcers. A standardized protocol for taking the photographs has been created -1 designated camera with fixed settings will be used on a standardized background in the same room, and an adhesive scale will be used to enable calibration. All present ulcers will be included in calculating the ulcer area. New or recurring ulcers are separately coded in the trial CRF. Additionally, we would like to underscore that the primary objective is to assess the safety of the treatment. We will assess multiple outcome parameters for efficacy, but do not expect sufficient power to be able to validate them as endpoints. In addition to ulcer area, traditionally used outcome parameters for ulcers, such as the number of ulcers, the number of new/healed ulcers, as well as patient-reported measures will be assessed (see the outcomes section lines 324-335 (lines 278-298 in the clean version) for more details).
We have edited the text in the outcomes section to more clearly reflect the primary objective of the trial.
Reviewer 2 1) DU activity in SSc patients is depend on the temperature. DU in SSc patients usually deteriorates in the winter, and improves in the summer. When will you start this clinical trial? It is necessary to define the starting time in this trial. If placebo control injection is initiated in the summer, DU may be improved by the increasing temperature, even if the placebo is injected.
We are indeed aware of the seasonal course of digital ulcers; this is an important reason for conducting this trial in a placebo-controlled fashion. Patients will be randomized to either placebo or verum in blocks (with the block size unknown to the investigators). This will aid in controlling for seasonal variation.
Reviewer 3 1) The introduction is to long, the authors should summarize it and further expand the discussion, underlining advantages and disadvantages of the procedures.
We have revised the introduction and the discussion. The considerations for each protocol element are discussed within the main text of the 'methods' session, as this significantly improved the readability of the paper. We thank the reviewer for their suggestion of specific literature to include in the discussion. We have moved the paragraph on studies on local cell implantation in SSc from the introduction to the discussion and expanded the discussion of existing cell based treatments for digital ulcers in SSc. 
VERSION 2 -REVIEW REVIEWER

GENERAL COMMENTS
The authors have addressed some of my concerns but have glossed over several important ones. I would like to see this study performed but if I were the funding agency I would still have some doubts that my money is being well spent. Some changes in design and especially in data analyses would make a big difference 1. A larger trial will be deemed feasible if the treatment safe and if recruitment for this trial can be completed within a reasonable time (12 months).
Comment: perhaps reword as follows: We do not yet know the number we will require in a definitive trial. The rate of recruitment in this pilot will inform our decision regarding recruitment feasibility for a larger trial based on the calculated sample size and recruitment duration. As there will only be 10 patients in the treatment group, we understand that the incidence of adverse events in this trial may be a poor estimate of the expected incidence in a larger trial. If however there are any serious AEs definitely attributable to the treatment we will have to reconsider the definitive trial or its design.
2. various outcome measures for efficacy will be assessed to assess their feasibility as an outcome as well as inform future power calculations. These outcome measures include change in patientsreported ulcer pain, quality of life as assessed with validated questionnaires (SF-36, S-HAQ, EQ5D), hand function as assessed with the Cochin Hand Function Scale, number of digital ulcers at 12 weeks, healing of ulcers at 12 weeks, area of digital ulcers, the need to alter the medication regime during the study as determined by the patient's own rheumatologist, the severity of SSc as assessed with the………(plus other information re outcome measurement in other paragraphs) 3. I do not feel they have adequately addressed my previous comment: "Although they are correct that in a large study there will be a need for a placebo arm, that is not necessarily true for this size study. How exactly will the placebo arm help them? I suppose one possibility would be to see if observers can remain blinded to the type of injection, perhaps biased by local side effects. But they have to show us the relevance of the placebo group based on their ultimate goals and data analyses rather than referring to statement about the need for placebo in large phase 3 trials."
This is really not a true phase 2 trial. This is a small feasibility trial. They want to see how many cases have side effects, how feasible recruitment is, how feasible it will be to give out XX questionnaires and make YY measurements over a certain period of time, what the best primary outcome will be for a larger trial……..
They are absolutely correct that trials in SSc require controls. However, with 10 cases in each group I doubt that any efficacy could be assessed even with controls. The investigators must ask themselves how controls in this small trial really helps them achieve important goals. For example, re toxicity, it is very likely that if there are serious adverse events they will be able to tell if they seem to be due to the treatment. So having 20 treated cases double the likelihood of seeing those side effects. The control group is as unlikely to be able to help determine what side effects are due to drug as it will be helpful in deciding what efficacy outcomes are due to drug vs chance.
I strongly support this team in their efforts and I would like to see the best information come out of this small study as possible. I do not feel that the control group adds anything at all to the protocol and in fact that it most likely detracts from certain aspects such as assessing toxicity. All the goals can essentially be achieved without a control group, except, as far as I can see, an assessment of blinding, which they have not addressed.
The authors have repeatedly reminded me that the primary outcome is assessment of toxicity. I understand that but there are other important outcomes as well such as feasibility of performing all procedures and outcome measures, recruitment, deciding on a primary outcome for a larger trial etc. Pilot studies are important and worthwhile investing in IF it is crystal clear how the results will be analysed to inform a larger study. How will you assess whether you will go ahead with a large trial if there are side effects? How will you decide if capillaroscopy is worthwhile including in a large trial based on the data from this trial? What exactly will you do with all your outcome measures to decide which should be the primary outcome in the large trial? There are many such questions that I have about this trial. You have not provided these details and instead have included many generalities. Although data for such trials are not analyzed as for a large trial, they are nonetheless analyzed with different purposes in mind. Pilot trials have their own intrinsic methodology aimed at their own intrinsic goals different from large trials.
REVIEWER
Stefano Bonomi
Plastic and Reconstructive Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano REVIEW RETURNED 28-Jan-2018
GENERAL COMMENTS
The authors made the required revisions
VERSION 2 -AUTHOR RESPONSE
The authors have addressed some of my concerns but have glossed over several important ones. I would like to see this study performed but if I were the funding agency I would still have some doubts that my money is being well spent. Some changes in design and especially in data analyses would make a big difference
While the reviewer highlights many important considerations, we would like to point out that our study was granted within the ZonMw Translational Adult Stem cell programme.
From the website of the ZonMW Translational Adult Stem cell programme: "A great deal of promising translational research on the use of adult stem cells to treat various conditions is already taking place.
(…) However, major problems with regard to funding were observed in the phase of translating research to clinical application arise. Before patients can be exposed to a new application in an experimental setting, it must be demonstrated that the therapy is safe and likely to be effective. (…)This grants programme is therefore designed to help translate adult stem cell research to clinical practice." (https://www.zonmw.nl/en/research-and-results/translationalresearch/programmas/programme-detail/translational-adult-stem-cell-research/t/background/).
Important considerations to fund this particular trial, as communicated by ZonMw, were the high unmet clinical need, to bridge the knowledge gap between case reports and a full trial, and the need for pilot data to enable larger, more rigorous trials. The limitations of a small clinical trial are fully known and did not form a barrier to funding this trial, with the aim to provide informed decisions for further clinical studies.
A larger trial will be deemed feasible if the treatment safe and if recruitment for this trial can be completed within a reasonable time (12 months).
Comment: perhaps reword as follows: We do not yet know the number we will require in a definitive trial. The rate of recruitment in this pilot will inform our decision regarding recruitment feasibility for a larger trial based on the calculated sample size and recruitment duration. As there will only be 10 patients in the treatment group, we understand that the incidence of adverse events in this trial may be a poor estimate of the expected incidence in a larger trial. If however there are any serious AEs definitely attributable to the treatment we will have to reconsider the definitive trial or its design.
We have revised the paragraph starting on line 300 based on the suggested text: The rate of recruitment in this pilot will inform our decision regarding recruitment feasibility for a larger trial based on the calculated sample size and recruitment duration. As there will only be 10 patients in the treatment group, we understand that the incidence of adverse events in this trial may be a poor estimate of the expected incidence in a larger trial. If however there are any serious AEs definitely attributable to the treatment according to the WHO-guidelines for pharmacovigilance, we will reconsider the definitive trial or its design. The reviewer is correct that evaluating outcomes is part of the feasibility aspect of this study. Studies in SSc are limited by low disease prevalence, which limits patient numbers and leads to a heterogeneity of presentation. This heterogeneity complicates monitoring of disease progression and provides few consistent 'hard' clinical endpoints. In the definitive trial the low number of observed endpoints will similarly be a problem for adequate power of the trial.
various outcome measures for efficacy will be assessed to assess their feasibility as an
We therefore aim to construct a composite endpoint that reflects morbidity but also occurs frequently enough for a medium-sized trial. We believe it unwise to commit ourselves too much, at this early phase, to an analysis that has many variables and considerations.
Our current idea is to use ulcer healing as an index parameter and assess the relation between number of healed ulcers and the various other outcome parameters (e.g. quality of life sub-questions, capillaroscopy etc.) to see if we can find more sensitive markers for improvement. We will attempt to identify parameters that associate with overall improvement, but are not redundant with regards to ulcer size. Aside from relationship to the index parameter, we will also examine reproducibility, observer dependency etc. of outcome measures.
We do not elaborate on this greatly in the body text, as this inherently is not a pre-specified (or prespecifiable) analysis, and will contain a certain amount of clinical intuition. We thank the reviewer for their support of our efforts, and hope to further elucidate our reasoning. The reviewer is correct in stating the group size presents limitations, even for the evaluation of the primary safety outcome. We still believe that the current approach is our best option at the current stage of knowledge. The rationale for a placebo group is threefold: 1) the need for a control group in a timevariable disease 2) to account for 'stem cell trial specific placebo effects' and 3) to be able to distinguish local injection responses from a response to the treatment (cells).
I do not feel they
1. The clinical course of digital ulcers in patients with SSc is seasonal, and it is likely that a 'regression to the mean' effect will confound our results.
2.
In addition to what might be considered normal clinical improvement, we also have reason to believe that especially in stem cell interventions, there is a considerable placebo effect. In an analysis of stem cell trials for cardiac disease, early small uncontrolled trials showed an effect whereas later more rigorously designed RCTs did not 1 . A similar trend was seen in a meta-analysis of clinical trials with CD34+ cells in critical limb ischemia -after promising, small uncontrolled studies, studies that included a placebo cohort showed that cell administration did not have additional benefits over placebo 2 .
3. Adding a placebo group better allows us to distinguish adverse events caused by the injection protocol itself from adverse events associated with injection of the MSCs. The reviewer correctly observes that there are many outcomes of the proposed study that do not pertain directly to patient health, but rather to the design of future trials.
The aim of this pilot is indeed to explore various outcome measures, and gain more insight into which outcome measure would be most suitable for a larger trial, especially with regard to creating a composite outcome measure. We felt that it is not possible at this stage to confidently answer the questions the reviewer asks above, to provide rigid 'cut off values' that will merit outcomes to be included in a larger trial. There are simply too many unknown variables. We can speculate, but we will very likely face unexpected hurdles and considerations.
In the present document we therefore intentionally restrict ourselves to concrete statements about the safety aspect of the study only. We furthermore commit ourselves to recording and reporting on all the secondary efficacy outcomes mentioned, which then will be available for the design of future trials. Data collected within the trial will be made publicly available; we added a data sharing statement to the protocol document (line 371).
Once we have completed the pilot trial, we will present a (proposed) analysis of the secondary outcomes, which will examine the robustness of our chosen (likely combined) outcome and give an indication of the sample sized needed for a definitive trial. Thus, we believe the design document of the next trial may be a more fruitful place for speculation, when we actually have the data to base our assumptions on. 
GENERAL COMMENTS
I do not feel that the authors have adequately addressed my previous comments. They are absolutely correct that a full trial requires a control group and that even a phase II trial needs one. But this is really a feasibility trial and their arguments do not apply. Even a very preliminary feasibility study such as this does need some thought ahead of time as to how the results will be interpreted. of course some things cannot be anticipated but they need some type of structure so that a reviewer can appreciate how they will deal with results.
VERSION 3 -AUTHOR RESPONSE
Reviewer comment: I do not feel that the authors have adequately addressed my previous comments. They are absolutely correct that a full trial requires a control group and that even a phase II trial needs one. But this is really a feasibility trial and their arguments do not apply. Even a very preliminary feasibility study such as this does need some thought ahead of time as to how the results will be interpreted. of course some things cannot be anticipated but they need some type of structure so that a reviewer can appreciate how they will deal with results.
We have edited the manuscript to better address the reviewer's comments. We revised the section on the rationale of the two-armed design, which focuses on feasibility aspects. We describe how the placebo arm will allow us to 1) assess the willingness of participants to be randomized and 2) assess the efficacy of the blinding strategies utilized (see lines 176-208; see lines 360-377 for details on the procedures). A placebo group is greatly preferable to our trial design, including the feasibility aspect. The possibility of randomization to placebo may in itself be a factor that affects patient's choice to participate in the trial, as we have observed in a previous trial with progenitor cells. In preliminary conversations with patients we learned that patients were daunted by injections in the hand. It is easily conceivable that patients' decision to participate will be swayed if there is a chance that the injection will contain the placebo and this needs to be taken into account for feasibility expectations. Similar arguments apply to the primary safety endpoint of local toxicity. There is little to no experience with palmar IM injections in this patient population and it possible that the proposed injection volumes, -sites etc. may lead to complications in some patients. These may be relatively simple complications that are more related to the injections themselves, rather than the MSC product. Adding a placebo group will allow us to pinpoint these problems and modify the protocol where necessary for the definitive trial. Incidentally we have tested the protocol with saline in healthy volunteers and observed no problems.
Regarding the efficacy outcomes: please note that many outcomes are highly subjective and interpretation is likely influenced by expectations of the trial outcome. Even the interpretation of the seemingly objective outcomes, e.g. assessment of ulcer improvement by an independent assessor on the basis of pictures, may be compromised if either photographer or assessor know a priori that all patients received the treatment. While the study is certainly not powered for efficacy, we do need the recording of outcomes, both by patients and trial physicians to be as objective as possible, in order to select outcomes for the following efficacy trial (see below).
The section on follow-up & outcomes has been revised to reflect the three aims of the trial (assessment of safety, efficacy and feasibility) in a more structured way. Furthermore, we amended and expanded the procedure for designing the follow-up trial (see lines 351-358). Outcomes will be discussed with an expert group. Through a Delphi approach, the association between the outcomes and expert opinion on the patient's improvement will be assessed. This will also enable us to determine whether a binary outcome (healing/no healing) or a continuous outcome (percentage of ulcer healing) is most appropriate. Additionally, we have expanded on the role of the data safety monitoring board (DSMB) in determining feasibility (see lines 364-366). During and after the trial, safety outcomes will be discussed with the DSMB (which also contains a scleroderma expert); in case of treatment related SAEs, a follow-up trial will not be commenced.
